May 23 |
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
|
May 14 |
Precigen GAAP EPS of -$0.10 misses by $0.01, revenue of $1.07M misses by $0.41M
|
May 14 |
Precigen Reports First Quarter 2024 Financial Results and Business Updates
|
May 13 |
Precigen Q1 2024 Earnings Preview
|
May 8 |
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
|
Apr 24 |
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
|
Apr 24 |
Actym Therapeutics Appoints Thomas Smart as CEO
|
Mar 28 |
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
|
Mar 22 |
J.P. Morgan cuts Precigen to underweight, cites burn rate
|
Mar 20 |
Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript
|